Prevention of
Coronary Artery Disease and Lipid Lowering
|
|
| Summary
Slides ATP 3 Update by Grundy et al Meta-analysis of the Impact of HMG reductase inhibitors on clinical events National Cholesterol Education Program (NCEP), L-TAP, NHANES CHAMP Combination Hemotherapy and Mortality Prevention Study |
LDL Lowering
4S Scandinavian Simvastatin Survival Study Group--Simvastatin vs placebo for mortality in coronary heart disease 4S Diabetes 4S Elderly and Women 4S Stroke A to Z Efficacy and safety of unfractionated heparin (UFH) versus enoxaparin as adjunctive therapy to baseline treatment with tirofiban and aspirin ACTIVATE IVUS trial of ACAT Inhibition AFCAPS/TexCAPS Lovastatin vs. placebo for primary prevention of CAD events ALLHAT Lipid-Lowering Trial Pravastatin vs usual care for the treatment of moderate hypercholesterolemia ARBITER-2 Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ASTEROID Atherosclerosis regression on IVUS
AVERT Atorvastatin Versus Revascularization Treatments (updated) CARE Cholesterol and Recurrent Events EASE Efficacy and safety of ezetimibe compared with placebo added to a stable dose of any statin in patients with high LDL cholesterol How Aggressive do we get on Lipids? Christopher P. Cannon, MD IDEAL Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering LIPID Long-Term Intervention With Pravastatin in Ischemic Disease Trial MEGA Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese PROVE IT-TIMI 22 Pravastatin or atorvastatin evaluation and infection therapy REVERSAL Reversing Atherosclerosis With Aggressive Lipid Lowering Safety and Tolerability of 80 mg of Simvastatin Long-term experience of patients with hypercholesterolemia SAGE Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease. Deedwania et al. Circulation. 2007 Feb 13; 115: 700 - 707 TNT High-dose vs low-dose atorvastatin to achieve an LDL of 100 mg/dl among patients with stable CHD WOSCOPS The West of Scotland Coronary Prevention Study--Pravastatin for primary prevention of CHD death |
HDL
Raising Impact of Simvastatin on HDL (AJC 1999) Effects of high doses of simvastatin and atorvastatin on HDl and apolipoprotein Impact of Simvastatin on HDL (ACC 2000) Simvastatin increases HDL-C and apolipoprotein A-1 compared to atorvastatin Statins, HDL-C, and Regression of Coronary Atherosclerosis Nicholls SJ, et al. JAMA. 2007 Feb; 297(5): 499-508 VA-HIT Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Other Lipid Lowering ACTIVATE ACAT Inhibition on the Progression of Coronary Atherosclerosis BIP Bezafibrate Infarction Prevention Study OmniHeart OmniHeart Feeding Study OmniHeart DASH Diet vs DASH with higher protein content
Obesity RIO Europe A Randomized Double-Blind Study of Weight Reducing Effect and Safety of Rimonabant in Obese Patients With or Without Comorbidities RIO Lipids Rimonabant in Obesity Smoking Cessation STRATUS-US Smoking Cessation in Smokers Motivated to Quit Vitamins Women's Health Study: Vitamin E in Primary Prevention Treatment with vitamin E for the primary prevention of cardiovascular disease in women NORVIT High-dose vitamin B compared with placebo among patients with ST elevation myocardial infarction |